News on urine-based diagnostic testing.
The test leverages a novel cancer biomarker that may improve the accuracy and sensitivity of noninvasive bladder cancer testing.
The self-testing device is designed for the measurement of urine pH levels in patients taking alkalizing and acidifying urinary treatments.
The company posted higher total sales for the first half of its fiscal year 2020 on sales growth in both in Japan and internationally.
The test, called Fujifilm SILVAMP TB LAM, was found to be about 30 percent more sensitive than the Alere Determine TB LAM Ag test from Abbott.
An assay based on a simple dye-protein interaction is now in clinical trials, with recent research suggesting it can accurately detect preeclampsia.
